S-A. McLachlan
St Vincent's Hospital Melbourne · 18 works · 188 citations · h-index 4
Top works
- Rapid screening for depression – validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients
- Life beyond a diagnosis of glioblastoma: a systematic review of the literature
- LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
- 395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
- LBA3: Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC
- LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses
- 565P RATIONALE-306: Long-term quality-adjusted survival comparison of tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line (1L) treatment for advanced or metastatic oesophageal squamous cell carcinoma (ESCC)
- 262P EGFR mutations (EGFR+) or ALK rearrangements (ALK+) in the BR31 trial of adjuvant durvalumab (D) v placebo (P)
- A pilot study to assess patient preferences for adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC)
- Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study
- 84P A multi-centre analysis of metastatic colorectal cancer diagnosed under the age of 35: A molecularly distinct group?
- 147P Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study
- 107P Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
- Abstract P4-13-10: Do BRCA1 and BRCA2 mutation carriers have an earlier natural menopause than their non-carrier relatives: A study from the Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab).
- Complementing co-attraction: The role of the complement factor C9 in the collective migration of the neural crest
- 2244P Borderline and locally advanced pancreatic cancer: Using real-world data to explore presentation, treatment patterns and outcomes
- Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB)
- 280P Efficacy and safety of ivosidenib in Australian and South Korean patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study